Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 202914-84-9
2. Bms 201038-04
3. Lomitapide (mesylate)
4. Aegr-733 Mesylate
5. Bms-201038-04
6. Lomitapide Mesilate
7. Lomitapide Mesylate [usan]
8. Aegr-733 Mesilate
9. X4s83cp54e
10. Chebi:72299
11. 202914-84-9 (mesylate)
12. N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide Methanesulfonate
13. Lomitapide Mesilate (jan)
14. Lomitapide Mesylate (usan)
15. N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide Methanesulfonate
16. Lomitapide Mesilate [jan]
17. 9h-fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-, Methanesulfonate
18. Methanesulfonic Acid;n-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
19. Unii-x4s83cp54e
20. Juxtapid (tn)
21. N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)biphenyl-2-yl)carbonyl)amino)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide Methanesulfonate
22. N-(2,2,2-trifluoroethyl)-9-{4-(4-({(4'-(trifluoromethyl)biphenyl-2-yl)carbonyl}amino)piperidin-1-yl)butyl}-9h-fluorene-9-carboxamide Methanesulfonate
23. N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidin-1-yl]butyl}-9h-fluorene-9-carboxamide Methanesulfonate
24. Lojuxta (tn)
25. Lomitapide Monomesylate
26. Lomitapide Methanesulfonate
27. Bms-201038 Mesylate
28. Schembl2731380
29. Chembl2105662
30. Dtxsid60174170
31. Ex-a502
32. Bms-201038ma
33. Glxc-25701
34. Amy38734
35. Bcp10696
36. Cia91484
37. Lomitapide Mesilate [who-dd]
38. Mfcd19443682
39. S7633
40. Akos025149431
41. Ccg-270481
42. Cs-3424
43. Lomitapide Mesylate [orange Book]
44. Ac-33863
45. As-56518
46. Da-33433
47. Hy-14668
48. Ft-0700260
49. D09638
50. J-690260
51. Q27139887
52. 1-(4-{9-[(2,2,2-trifluoroethyl)carbamoyl]-9h-fluoren-9-yl}butyl)-4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidinium Methanesulfonate
53. 2059395-52-5
54. 9h-fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-, Methanesulphonate
55. Aegr-733 Mesylate;bms-201038 Mesylate;aegr733 Mesylate;bms201038 Mesylate;aegr 733 Mesylate;bms 201038 Mesylate
56. N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)biphenyl-2-yl)carbonyl)amino)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide Methanesulphonate
57. N-(2,2,2-trifluoroethyl)-9-[4-(4-{2-[4-(trifluoromethyl)phenyl]benzamido}piperidin-1-yl)butyl]-9h-fluorene-9-carboxamide; Methanesulfonic Acid
Molecular Weight | 789.8 g/mol |
---|---|
Molecular Formula | C40H41F6N3O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 10 |
Exact Mass | 789.26711156 g/mol |
Monoisotopic Mass | 789.26711156 g/mol |
Topological Polar Surface Area | 124 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 1200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Juxtapid |
PubMed Health | Lomitapide (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | JUXTAPID capsules contain lomitapide mesylate, a synthetic lipid-lowering agent for oral administration.The chemical name of lomitapide mesylate is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-pi |
Active Ingredient | Lomitapide mesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 5mg base; eq 20mg base; eq 10mg base |
Market Status | Prescription |
Company | Aegerion |
2 of 2 | |
---|---|
Drug Name | Juxtapid |
PubMed Health | Lomitapide (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | JUXTAPID capsules contain lomitapide mesylate, a synthetic lipid-lowering agent for oral administration.The chemical name of lomitapide mesylate is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-pi |
Active Ingredient | Lomitapide mesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 5mg base; eq 20mg base; eq 10mg base |
Market Status | Prescription |
Company | Aegerion |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Lomitapide Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lomitapide Mesylate, including repackagers and relabelers. The FDA regulates Lomitapide Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lomitapide Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lomitapide Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lomitapide Mesylate supplier is an individual or a company that provides Lomitapide Mesylate active pharmaceutical ingredient (API) or Lomitapide Mesylate finished formulations upon request. The Lomitapide Mesylate suppliers may include Lomitapide Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Lomitapide Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lomitapide Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Lomitapide Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Lomitapide Mesylate DMFs exist exist since differing nations have different regulations, such as Lomitapide Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lomitapide Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Lomitapide Mesylate USDMF includes data on Lomitapide Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lomitapide Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lomitapide Mesylate suppliers with USDMF on PharmaCompass.
A Lomitapide Mesylate written confirmation (Lomitapide Mesylate WC) is an official document issued by a regulatory agency to a Lomitapide Mesylate manufacturer, verifying that the manufacturing facility of a Lomitapide Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lomitapide Mesylate APIs or Lomitapide Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Lomitapide Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Lomitapide Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lomitapide Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lomitapide Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lomitapide Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lomitapide Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lomitapide Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lomitapide Mesylate suppliers with NDC on PharmaCompass.
Lomitapide Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lomitapide Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lomitapide Mesylate GMP manufacturer or Lomitapide Mesylate GMP API supplier for your needs.
A Lomitapide Mesylate CoA (Certificate of Analysis) is a formal document that attests to Lomitapide Mesylate's compliance with Lomitapide Mesylate specifications and serves as a tool for batch-level quality control.
Lomitapide Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Lomitapide Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lomitapide Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Lomitapide Mesylate EP), Lomitapide Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lomitapide Mesylate USP).
LOOKING FOR A SUPPLIER?